Vaximm AG, a subsidiary of OSR Holdings, Inc. and a leader in oral T-cell immunotherapies for cancer, has announced the appointment of Sébastien Wieckowski, PhD, as Chief Scientific Officer.
This strategic move strengthens the company’s leadership team with Dr. Wieckowski’s extensive expertise in the company’s core technology and research platform. Dr. Wieckowski brings a unique blend of experience in immunology and advanced data science, enabling him to integrate rigorous analytical workflows and data-driven strategies to accelerate discovery and optimize the performance of Vaximm’s oral immunotherapy platform.
Health Technology Insights: AHN Offers Innovative Low-Dose Radiation Therapy for Osteoarthritis
Dr. Andreas Niethammer, CEO of Vaximm, expressed his enthusiasm, stating that he has worked closely with Dr. Wieckowski since 2016 and has witnessed his deep understanding of the company’s oral vector technology. Dr. Niethammer emphasized that Dr. Wieckowski’s combination of scientific mastery and practical execution will be critical as Vaximm advances into later-stage clinical trials and expands its platform with new assets. The appointment comes at a key moment as Vaximm moves its lead candidate, VXM01, further into clinical development while exploring additional therapeutic targets. In his role as CSO, Dr. Wieckowski will oversee strategic improvements to the VXM platform, enhancing its capabilities and broadening its applications. Dr. Constance Höfer, Chief Scientific Officer of OSR Holdings, highlighted Dr. Wieckowski’s pivotal role in Vaximm’s research and development strategy, particularly in the development of VXM01. She noted that his leadership ensures a data-driven evolution of the platform, supporting its expansion across oncology and non-oncology indications while strengthening both scientific rigor and commercial potential.
Health Technology Insights: NeuraLight Unveils Scientific Leaders Advancing Neurology
Reflecting on his appointment, Dr. Wieckowski said he is honored to take on the role of CSO after being part of Vaximm’s journey for over a decade, from early academic research to industrial-scale development. He emphasized that his mission is to combine a deep understanding of immunology, particularly cell-based immunity, with advanced data science to develop precise and scalable therapies. By embedding integrated analytical frameworks into the R&D process, Dr. Wieckowski said Vaximm is advancing next-generation programs at the forefront of biomedical research to deliver cost-effective and patient-focused treatments with transformative potential across multiple therapeutic areas where precise targeting, safety, and tolerability are critical.
Health Technology Insights: Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
